View IR Calendar

Upcoming Event

2023 ASCO Annual Meeting

Jun 2–June 6, 2023

Chicago, Illinois

Friday, June 2, 2023

Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
Session: Breast Cancer-Local/Regional/Adjuvant
Oral Abstract Presentation: Hall D1, 2:45 p.m. CT
Abstract Number: 502

Sunday, June 4, 2023

A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)
Session: Breast Cancer-Local/Regional/Adjuvant
Poster Session: 8:00-11:00 a.m. CT
Abstract Number: TPS620
Poster Board: 447b

Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer
Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Session: 8:00-11:00 a.m. CT
Abstract Number: 8535
Poster Board: 162

Circulating tumor DNA (ctDNA) monitoring in patients with breast cancer receiving neoadjuvant palbociclib and endocrine therapy. A secondary analysis of the NeoRHEA phase 2 study
Session: Breast Cancer-Local/Regional/Adjuvant
Poster Session: 8:00-11:00 a.m. CT
Abstract Number: 601
Poster Board: 431

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer
Session: Lung Cancer - Non-Small Cell Metastatic
Poster Session: 8:00-11:00 a.m. CT
Abstract Number: 9019
Poster Board: 7
*Also part of Poster Discussion Session, June 4th at 4:30pm CT, Lung Cancer- Non-Small Cell Metastatic

Monday, June 5, 2023

Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Session: Head and Neck Cancer
Poster Session: 1:15-4:15 p.m. CT
Abstract Number: 6065
Poster Board: 57

Email Alerts

Sign up for email alerts for Press Releases & SEC Filings

Sign Up